RetroSense Therapeutics For Profit
.jpg)
A Tokyo-based clinical-stage biotech company. Lead program TMS-007 (acute ischemic stroke) is partnered with Biogen.
Investors
Technology:
Other
Industry:
Regenerative medicine
Headquarters:
United States
Investors Number:
12
Total Funding:
$106M
Estimated Revenue:
$50M to $100M
Last Funding Type:
Venture - Series Unknown
Register and Claim Ownership